CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 136 enrolled
Drug / intervention
HeartWare Ventricular Assist Devicedevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03697980
NCT03697980N/ACompleted

Apogee, A HeartWare HVAD Destination Product Surveillance Registry (PSR) Platform

Medtronic Cardiac Rhythm and Heart Failure·observational·Posted Oct 5, 2018·Updated Dec 4, 2023

In Brief

An observational study evaluating HeartWare Ventricular Assist Device for Chronic Heart Failure. Completed, enrolled 136 participants across 33 sites.

Detailed Summary

Medtronic is sponsoring the Apogee study to further enhance scientific understanding of the implant procedure, optimized blood pressure management, and anticoagulation/ antiplatelet therapy in patients receiving a Medtronic HeartWare™ Ventricular Assist Device (HVAD™) for destination therapy. The Apogee study is conducted within Medtronic's Product Surveillance Platform.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
20192020202120222023202420252026
First PostedOct 5, 2018
Enrollment StartJan 17, 2019
Primary CompletionFeb 10, 2022
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 7.7 years ago

Interventions

HeartWare Ventricular Assist Devicedevice

The HVAD is an implantable centrifugal rotary blood pump that is implanted in the pericardial space and is designed to provide up to 10 L/min of blood flow from the left ventricular to the aorta. The HVAD System is comprised of three major components: the HVAD (pump) with inflow and outflow conduits, a Controller (microprocessor unit that controls the operation of the HVAD), and power sources (AC and DC power adapters that provide power to the Controller and implanted HVAD).